ライフサイエンスコーパス: alpha-interferon

1 syl-uridine), alpha interferon, or pegylated alpha interferon.

2 to inhibit the antiviral response induced by alpha interferon.

3 nd E2, and HCV replication was suppressed by alpha interferon.

4 on for PKR activation in vivo in response to alpha interferon.

5 sed by production of soluble factors such as alpha interferon.

6 ufficient to render translation resistant to alpha interferon.

7 followed by maintenance therapy with DEX and alpha interferon.

8 TNF-alpha was greater than that of gamma or alpha interferon.

9 of the 2-5A system in the anti-HIV effect of alpha interferon.

10 rted to increase the therapeutic response to alpha interferon.

11 ay be preventable by treating the donor with alpha-interferon.

12 ed therapies for chronic hepatitis C are the alpha interferons.

13 ression of gamma interferon, interleukin-18, alpha interferon 16, and RNase L.

14 Additional BLT mice were treated with human alpha interferon 2b (IFN-alpha2b) (intron A) and assesse

15 Treatment with alpha interferon A/D cured the blasticidin-resistant Huh

16 All patients received alpha-interferon after transplantation, and the overall

17 ure to proinflammatory cytokines such as TNF-alpha +/- interferon alpha/beta has marginal effects on

18 e ability of intranasal treatment with human alpha interferon (alpha-IFN) to reduce lung and nasal wa

19 B-cells during cell cycle exit triggered by alpha-interferon (alpha-IFN).

20 8, prostaglandin E(2), tumor necrosis factor-alpha, interferon-alpha, and albumin were examined.

21 and a synergistic effect was observed, with alpha interferon and interferon-inducible protein 10 und

22 orrelated with increased pulmonary levels of alpha interferon and interleukin-1beta in pigs infected

23 itis C virus (HCV) infection using pegylated alpha interferon and ribavirin leads to sustained cleara

24 Pegylated alpha interferon and ribavirin therapy for hepatitis C v

25 virin to alpha interferon, the pegylation of alpha interferon, and the demonstration that sustained v

26 atment part, four patients were treated with alpha-interferon, and all were able to undergo the reint

27 th a Us11 mutant virus are hypersensitive to alpha interferon, arresting translation upon entry into

28 aternal antibodies and that the provision of alpha interferon as an additional signal leads to antibo

29 transplantation, the donor was treated with alpha-interferon at a standard dose.

30 were treated with a single dose of exogenous alpha interferon before infection.

31 xamined for tumor necrosis factor alpha (TNF-alpha), interferon beta (IFN-beta), interleukin 6 (IL-6)

32 des, transcribed large amounts of interferon-alpha, interferon-beta, and interleukin-12.

33 t autoantibodies directed against interferon-alpha, interferon-beta, interleukin-1alpha (IL-1alpha),

34 Bovine alpha-interferon (BoINF-alpha) is a single polypeptide p

35 ould be abrogated by antibodies neutralizing alpha interferon, but not interleukin 6 (IL-6).

36 In contrast to Epo, alpha interferon can induce STAT1 phosphorylation and DN

37 ere used either alone or in combination with alpha-interferon, chlorambucil, or interleukin-2 (IL-2).

38 Since human CSF-1 stimulates secretion of alpha interferon from mononuclear cells and BARF1 encode

39 (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), interferon gamma (IFN-gamma), and granulocyte ma

40 n-8 (IL-8), tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and IL-1beta in ai

41 Tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), and interferon alf

42 m levels of tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma), interleukin-12p40

43 ls of serum tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFNgamma), MCP-1, MCP-5, sTNRF

44 Production of tumor necrosis factor alpha, interferon gamma (IFN-gamma), and prostaglandin E

45 leukin (IL)-12, IL-10, tumor necrosis factor alpha, interferon gamma (IFN-gamma), and transforming gr

46 cell-derived cytokines tumor necrosis factor alpha, interferon gamma, and granulocyte/macrophage colo

47 Mean plasma levels of tumor necrosis factor alpha, interferon gamma, and interferon gamma-induced pr

48 n of NK cell-enhancing cytokines (interferon alpha, interferon gamma, and interleukin 12).

49 al burden or levels of tumor necrosis factor alpha, interferon gamma, interleukin 6, soluble CD14, or

50 fic agonist, abrogated tumor necrosis factor alpha/interferon gamma-induced apoptosis through pathway

51 tory genes (tumor necrosis factor alpha [TNF-alpha], interferon gamma [IFN-gamma], and interleukin 8

52 cytokines (tumor necrosis factor alpha [TNF-alpha], interferon gamma [IFN-gamma], transforming growt

53 tumor necrosis factor alpha, interleukin 10, alpha interferon, gamma interferon, prostaglandins, or r

54 IL-12 p40, tumor necrosis factor alpha (TNF alpha), interferon-gamma (IFN gamma), and granulocyte-ma

55 es, such as tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), and interleukin 6

56 oduction of tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), interleukin 10 (IL

57 ls of serum cytokines (tumor necrosis factor-alpha, interferon-gamma and interleukin-1beta, -2, -4, -

58 e BLyS and APRIL upon exposure to interferon-alpha, interferon-gamma or CD40 ligand.

59 eases in the levels of tumor necrosis factor-alpha, interferon-gamma, and active transforming growth

60 ta, IL-6, IL-10, tumor necrosis factor (TNF)-alpha, interferon-gamma, and granulocyte-macrophage colo

61 ured and production of tumor necrosis factor-alpha, interferon-gamma, and IL-10 were assessed by immu

62 ites tested for interleukin (IL)-1beta , TNF-alpha, interferon-gamma, and IL-6 was obtained from rats

63 s revealed decrease of tumor necrosis factor-alpha, interferon-gamma, and inducible nitric oxide synt

64 y mediators, including tumor necrosis factor alpha, interferon-gamma, and inducible nitric oxide synt

65 evels of the cytokines tumor necrosis factor-alpha, interferon-gamma, and interleukin-10.

66 reas reduced levels of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 were detected

67 In general, peak tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 levels were d

68 6, IL-9, IL-11, IL-15, tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharide fail to

69 ith interleukin-1beta, tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharide.

70 interleukins 6 and 8, tumor necrosis factor-alpha, interferon-gamma, and matrix metalloproteinase-2

71 ng growth factor-beta, tumor necrosis factor-alpha, interferon-gamma, and MCP-1; specific cell types,

72 Requirements for tumor necrosis factor-alpha, interferon-gamma, and monocyte chemoattractant pr

73 derived growth factor, tumor necrosis factor-alpha, interferon-gamma, and phorbol 12-myristate 13-ace

74 antly higher levels of tumor necrosis factor-alpha, interferon-gamma, and regulated on activation nor

75 in-12, interleukin-13, tumor necrosis factor-alpha, interferon-gamma, C-reactive protein, and procalc

76 of interleukin (IL)-6, tumor necrosis factor-alpha, interferon-gamma, IL-10, monocyte chemotactic pro

77 induced mice including tumor necrosis factor-alpha, interferon-gamma, interleukin (IL)-2, IL-9, IL-12

78 iver tissue, including tumor necrosis factor alpha, interferon-gamma, interleukin (IL)-6, IL-12, and

79 and chemokines such as tumor necrosis factor-alpha, interferon-gamma, interleukin 10 (IL-10), and CXC

80 uring acute rejection: tumor necrosis factor-alpha, interferon-gamma, interleukin- (IL) 1beta, IL-2,

81 evaluate inflammatory (tumor necrosis factor-alpha, interferon-gamma, interleukin-6) and alloimmune (

82 tragraft inflammation (tumor necrosis factor-alpha, interferon-gamma, interleukin-6) and alloimmune a

83 nd increased levels of tumor necrosis factor-alpha, interferon-gamma, matrix metalloproteinase (MMP)-

84 llular activation with tumor necrosis factor-alpha, interferon-gamma, or lipopolysaccharide, as shown

85 es interleukin-1alpha, tumor necrosis factor-alpha, interferon-gamma, or transforming growth factor-b

86 (i.e., interleukin-2, tumor necrosis factor-alpha, interferon-gamma, perforin, and CD107a expression

87 tion and production of tumor necrosis factor-alpha, interferon-gamma, regulated on activation normal

88 actor 2, flt-3 ligand, tumor necrosis factor alpha, interferon-gamma-inducible 10-kd protein, granulo

89 protein-1, macrophage inflammatory protein-1 alpha, interferon-gamma-inducible protein of 10 kd, KC,

90 (2) also inhibited the tumor necrosis factor-alpha-, interferon-gamma-, and interleukin-1beta-mediate

91 ng anti-(alpha)-tumor necrosis factor (TNF), alpha-interferon-gamma (IFN-gamma), or alpha-interleukin

92 s were stimulated with tumor necrosis factor-alpha/interferon-gamma or reduced oxygen (<5 KPa).

93 nstitutively and after tumor necrosis factor-alpha/interferon-gamma stimulation.

94 ing (G-CSF, tumor necrosis factor-alpha [TNF-alpha], interferon-gamma [IFN-gamma], IL-10).

95 alpha-interferon gave a median TTNT of 8.7 months (95% C

96 NDV infection (which induces alpha interferon) had the same effect, and stimulation c

97 Alpha interferon has demonstrated efficacy in the treatm

98 Four forms of alpha interferon have been evaluated in large numbers of

99 de, is frequently resistant to the antiviral alpha interferon (IFN).

100 els and diminishes the response to exogenous alpha interferon (IFN).

101 ouble-stranded RNA, single-stranded RNA) and alpha interferon (IFN-alpha) and IFN-beta are produced.

102 The rapid induction of alpha interferon (IFN-alpha) and IFN-beta expression pla

103 By contrast, alpha interferon (IFN-alpha) and IFN-beta reduced expres

104 le in humans, it is a potent inducer of both alpha interferon (IFN-alpha) and IFN-beta) production, a

105 hMPV was a stronger inducer of both alpha interferon (IFN-alpha) and IFN-gamma responses tha

106 We have previously shown that both alpha interferon (IFN-alpha) and IFN-gamma signaling pat

107 inhibited the induction of multiple genes by alpha interferon (IFN-alpha) and IFN-gamma, including th

108 C(-/-) mice also displayed reduced levels of alpha interferon (IFN-alpha) and IgM in the serum, indic

109 his study, we investigated the production of alpha interferon (IFN-alpha) and inducible chemokines by

110 cause of the known stimulatory properties of alpha interferon (IFN-alpha) and interleukin-15 (IL-15),

111 ctivated by the cytokines interleukin 12 and alpha interferon (IFN-alpha) and plays a significant rol

112 only in a fraction of patients treated with alpha interferon (IFN-alpha) and ribavirin combination t

113 Although the combination therapy of alpha interferon (IFN-alpha) and ribavirin is effective

114 rom Huh-7 clones by prolonged treatment with alpha interferon (IFN-alpha) and that a higher frequency

115 lated genes (ISGs), we pretreated cells with alpha interferon (IFN-alpha) and then infected the cells

116 eatedly passaged in L-929 cells treated with alpha interferon (IFN-alpha) at levels of 25 U/ml.

117 ypically trigger the prodigious secretion of alpha interferon (IFN-alpha) by plasmacytoid dendritic c

118 Alpha interferon (IFN-alpha) controls homeostasis of hem

119 tical role in the production of TMEV-induced alpha interferon (IFN-alpha) during early viral infectio

120 BHK21 and Huh-7 cells and demonstrated that alpha interferon (IFN-alpha) effectively inhibited the r

121 nfection in vitro induced less IFN-gamma and alpha interferon (IFN-alpha) from CD1d-deficient splenoc

122 s (pDCs) are intrinsically unable to produce alpha interferon (IFN-alpha) in response to SIV RNA stim

123 rMP12-mPKRN167 induced alpha interferon (IFN-alpha) in sera, accumulated RVFV a

124 ccumulation of HCV RNA can be inhibited with alpha interferon (IFN-alpha) in vivo and in culture cell

125 Alpha interferon (IFN-alpha) induced tetherin and blocke

126 We found that CD46 Ads were capable of alpha interferon (IFN-alpha) induction by peripheral blo

127 Alpha interferon (IFN-alpha) is an approved medication f

128 a peak of induction that coincides with peak alpha interferon (IFN-alpha) levels in plasma, and that

129 Pretreatment of MECs with alpha interferon (IFN-alpha) prior to infection effectiv

130 dendritic cells (DCs) that corresponded with alpha interferon (IFN-alpha) production and a rapid decr

131 ding activity and, therefore, suppression of alpha interferon (IFN-alpha) production and IFN-mediated

132 l with regard to its potential for sustained alpha interferon (IFN-alpha) production and induction of

133 1c and CD86 as well as an increased level of alpha interferon (IFN-alpha) production compared to leve

134 Alpha interferon (IFN-alpha) production is triggered whe

135 Other than ganciclovir and alpha interferon (IFN-alpha) prophylaxis, no KSHV-associ

136 ncreased levels of H1N1 replication, reduced alpha interferon (IFN-alpha) protein synthesis, and no d

137 s with Tyk2, a signaling intermediate in the alpha interferon (IFN-alpha) signaling pathway, via a pr

138 Alpha interferon (IFN-alpha) suppresses human immunodefi

139 is C virus (HCV) infections are resistant to alpha interferon (IFN-alpha) therapy, subgenomic in vitr

140 MLN4924 only when T cells were treated with alpha interferon (IFN-alpha) to induce high levels of BS

141 depletion rendered cells less responsive to alpha interferon (IFN-alpha) treatment by impairing IFN-

142 Alpha interferon (IFN-alpha) treatment induces hematolog

143 Alpha interferon (IFN-alpha) treatment or overexpression

144 ocalize with Tas, even after upregulation by alpha interferon (IFN-alpha) treatment.

145 Alpha interferon (IFN-alpha) was implicated as at least

146 cordingly, BST-2 upregulation in response to alpha interferon (IFN-alpha) was shown to increase the s

147 ot study of 1-year treatment with lamivudine/alpha interferon (IFN-alpha) were investigated.

148 a hybrid replicons maintained sensitivity to alpha interferon (IFN-alpha), albeit with an eightfold-h

149 L-1beta, IL-12, tumor necrosis factor alpha, alpha interferon (IFN-alpha), and IFN-beta throughout th

150 In addition, the levels of CD83, CD11b, alpha interferon (IFN-alpha), and IFN-beta, but not IFN-

151 of the production of interleukin-12 (IL-12), alpha interferon (IFN-alpha), and IFN-gamma by the Ad-in

152 in-1beta (IL-1beta), IL-6, IL-10, IL-12 p40, alpha interferon (IFN-alpha), and IFN-gamma, it actively

153 ) this anti-HIV activity is partially due to alpha interferon (IFN-alpha), but not to IFN-gamma, IFN-

154 airway fluid levels of interleukin-6 (IL-6), alpha interferon (IFN-alpha), CXCL1 (keratinocyte chemoa

155 Indeed, at low doses of alpha interferon (IFN-alpha), IFITM-2 and -3 mediated mo

156 combinant human tumor necrosis factor alpha, alpha interferon (IFN-alpha), IFN-beta, or IFN-gamma for

157 Alpha interferon (IFN-alpha), IFN-gamma, and ribavirin e

158 ines, including tumor necrosis factor alpha, alpha interferon (IFN-alpha), interleukin-1 beta (IL-1 b

159 d dengue virus and induced the expression of alpha interferon (IFN-alpha), key cytokines, and cell ad

160 evidenced by significantly higher levels of alpha interferon (IFN-alpha), MIP-1alpha, and MIP-1beta

161 he mRNA expression of four immune modulators-alpha interferon (IFN-alpha), oligoadenylate synthetase

162 lations that displayed partial resistance to alpha interferon (IFN-alpha), telaprevir, daclatasvir, c

163 strate hepatitis C virus (HCV) inhibition by alpha interferon (IFN-alpha), the detailed inhibition ki

164 nce HSV-1 ICP0 mutants are hypersensitive to alpha interferon (IFN-alpha), we examined the effect of

165 onic hepatitis and is currently treated with alpha interferon (IFN-alpha)-based therapies.

166 onic hepatitis and is currently treated with alpha interferon (IFN-alpha)-based therapies.

167 Responses to alpha interferon (IFN-alpha)-based treatment are depende

168 Alpha interferon (IFN-alpha)-induced transcriptional act

169 The alpha interferon (IFN-alpha)-inducible restriction facto

170 of MxB to the HIV-1 restriction observed in alpha interferon (IFN-alpha)-treated human cells is unkn

171 sor differentially activated pDCs to produce alpha interferon (IFN-alpha).

172 ance to the innate immune program induced by alpha interferon (IFN-alpha).

173 tumor necrosis factor alpha (TNF-alpha) and alpha interferon (IFN-alpha).

174 Vero cells was suppressed by the addition of alpha interferon (IFN-alpha).

175 ly phosphorylated on tyrosine in response to alpha interferon (IFN-alpha).

176 duction of all cytokines investigated except alpha interferon (IFN-alpha).

177 istance to and significant side effects from alpha interferon (IFN-alpha).

178 UV-killed RSV or mock conditions, contained alpha interferon (IFN-alpha; median, 43 pg/ml) and IFN-l

179 P-1beta, RANTES, tumor necrosis factor (TNF)-alpha, interferon (IFN)-alpha, IFN-gamma, granulocyte-ma

180 as increased for tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and interleukin (IL)-10 a

181 H that expressed tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and interleukin (IL)-10 w

182 and secretion of tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, and interleukin (IL)-2 by

183 Alpha-interferon (IFN-alpha) is thought to play a pathog

184 efine a central role for type I interferons (alpha interferon [IFN-alpha] and IFN-beta) in severe dis

185 tective roles for antiviral cytokines (e.g., alpha interferon [IFN-alpha] and IFN-gamma) against WNV

186 Binding of alpha interferon (IFNalpha) to its receptors induces rap

187 ds, and reductions in the anti-HIV effect of alpha interferon in PBL and in Jurkat cells.

188 second- and third-wave viruses induced less alpha interferon in the infected mouse lungs.

189 Based on the first decade of research on alpha interferon in viral hepatitis, one can conclude th

190 Core, NS3, and NS5A can block the action of alpha interferon in vitro; hence, these genetic patterns

191 terferon alfa-2a resembles other recombinant alpha interferons in structure and pharmacology.

192 With the introduction of alpha-interferon in 1984, marked improvements in patient

193 BV also increased the antiviral activity of alpha-interferon in replicons.

194 latently infected B-cell lines they inhibit alpha interferon-induced apoptosis that is believed to b

195 Therefore, EBER inhibition of alpha-interferon-induced apoptosis, and potentially othe

196 alone protected Burkitt lymphoma cells from alpha-interferon-induced apoptosis.

197 ning transcription factor to be studied, the alpha-interferon-induced ISGF3, is composed of a Stat1:2

198 s sequence binding protein or IRF-7, a novel alpha interferon-inducible factor identified in this stu

199 ic variations in tumor necrosis factor (TNF)-alpha, interferon (INF)-gamma, transforming growth facto

200 chemistry, cumulative steroid, and OKT3 and alpha-interferon (INF) dose data were collected at the t

201 Treatment with alpha interferon is a standard therapy for patients with

202 standard therapy of chronic hepatitis C with alpha interferon is less than ideal, numerous other appr

203 Alpha interferon is the only drug that has been shown to

204 Alpha interferon is the only licensed drug for hepatitis

205 Our results demonstrate that IFN-alpha, interferon lambda (IFN-lambda) and RBV each inhib

206 ive in double-blind trials and low dose oral alpha interferon looks promising in initial open studies

207 mice with RSV rA2 line 19F resulted in lower alpha interferon lung levels 24 h postinfection, higher

208 The treatment of hepatitis C with alpha-interferon may allow the reintroduction of anti-TB

209 erved amino acid in each position of several alpha interferon nonallelic subtypes to generate a conse

210 he latent transcription factors activated by alpha interferon or gamma interferon contain the Stat1 p

211 of virological responders to either standard alpha interferon or peginterferon has demonstrated a pro

212 this effect could be reproduced either with alpha interferon or with an HCV NS5B inhibitor.

213 rimary blood mononuclear cells in vitro with alpha interferon or with Toll-like receptor (TLR) agonis

214 kine receptor inhibition; cytokine addition (alpha-interferon or interleukin-10); novel anti-metaboli

215 eloid leukemia (CML) patients, intolerant of alpha-interferon or with interferon-resistant disease.

216 o-5-methyl-beta-L-arabinofuranosyl-uridine), alpha interferon, or pegylated alpha interferon.

217 , is currently treated with either pegylated alpha interferon (pegIFN-alpha) or one of the five nucle

218 ant repression of Qp activity in response to alpha interferon, possibly mediated by either the interf

219 asmacytoid dendritic cells are the principal alpha interferon-producing cells (IPC), responsible for

220 wever, pretreatment of D2-Mx1(r/r) mice with alpha interferon protected them from lethal infections.

221 enhances PDL-1 expression and does so in an alpha interferon receptor (IFNAR) signaling-dependent ma

222 which is initiated through activation of the alpha interferon receptor (IFNAR), regulates the express

223 Moreover, we showed that alpha interferon reduced the accumulation of RNA-contain

224 We also show that alpha interferon represses RTA-mediated transactivation

225 scale screening of HCV-infected patients for alpha interferon-resistant HCV genotypes.

226 We report that recombinant alpha-interferon (rIFN-alpha) administration decreases t

227 utant BARF1 EBV showed reduced inhibition of alpha interferon secretion by human mononuclear cells wh

228 Recombinant BARF1 inhibited alpha interferon secretion by mononuclear cells in a dos

229 ressed from the EBV genome directly inhibits alpha interferon secretion, which may modulate the innat

230 ived from EBV-infected B cells could inhibit alpha interferon secretion.

231 in pediatric rheumatology, most notably the alpha interferon signature of systemic lupus erythematos

232 In vitro, alpha interferon stimulated the activation of MV-specifi

233 .003) and TRIM22 (P = 0.0006) in response to alpha interferon stimulation and increased expression of

234 ed in HEK293 cells treated with poly(I:C) or alpha interferon, suggesting a direct effect of virus in

235 to produce proinflammatory factors, such as alpha interferon, that play a critical role in inducing

236 A in the serum, the addition of ribavirin to alpha interferon, the pegylation of alpha interferon, an

237 However, in the majority of cases, alpha interferon therapy fails to resolve the chronic HB

238 The reason alpha interferon therapy is inefficient at resolving chr

239 Alpha interferon therapy of chronic hepatitis C is typic

240 associated with decreased responsiveness to alpha interferon therapy.

241 Ribavirin (RBV), used in combination with alpha interferon to treat hepatitis C virus (HCV) infect

242 uired for wild-type levels of replication in alpha interferon-treated cells and, along with the gamma

243 Alpha interferon treatment had a similar effect.

244 rm clinical and economic outcomes of current alpha interferon treatment regimens remains limited.

245 itis C is a life-shortening disease and that alpha interferon treatment, for 6 or 12 months, despite

246 Interestingly, alpha-interferon treatment was found to slowly revert th

247 esis of antiviral, proinflammatory cytokines alpha interferon, tumor necrosis factor alpha, and inter

248 esent on the biopsy specimen, treatment with alpha-interferon was begun and the anti-TB drugs were su

249 Alpha-interferon was used in four patients (two successf

250 and safety of interferon alfa-n3, a natural alpha interferon which contains multiple interferon spec

251 IPC exposed in vitro to HIV produce alpha interferon, which partially inhibits viral replica